866-997-4948(US-Canada Toll Free)

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 110 Pages

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2017

Summary

According to the recently published report 'Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H1 2017'; Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes.

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response.

The report 'Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H1 2017' outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviewsalso reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 4, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Cardiovascular which include indications Non-Small Cell Lung Cancer, Solid Tumor, Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Gastric Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Head And Neck Cancer Squamous Cell Carcinoma, Lung Adenocarcinoma, Metastatic Colorectal Cancer, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Bone Metastasis, Colon Carcinoma, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer, Hematological Tumor, Kidney Cancer (Renal Cell Cancer), Leukemias, Liposarcoma, Liver Cancer, Melanoma, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Neuroendocrine Tumors, Non-Rhabdomyosarcoma, Ocular Melanoma, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Peritoneal Cancer, Pheochromocytoma, Recurrent Glioblastoma Multiforme (GBM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Skin Cancer, Thrombosis, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer and Wilms' Tumor (Nephroblastoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
- The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Overview
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Astellas Pharma Inc
BerGenBio ASA
Betta Pharmaceuticals Co Ltd
Celldex Therapeutics Inc
Exelixis Inc
Ignyta Inc
Les Laboratoires ServierSAS
Mirati Therapeutics Inc
Ono Pharmaceutical Co Ltd
Oribase Pharma
Qurient Co Ltd
SignalChem Lifesciences Corp
Takeda Pharmaceutical Company Ltd
Tolero Pharmaceuticals Inc
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Drug Profiles
Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGB-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGB-324 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-9016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-053 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gilteritinib fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glesatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOPE-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody 3 to Inhibit AXL Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugate to Inhibit AXL Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-7475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit Axl Tyrosine kinase for Thrombosis and Non-Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXDX-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-49076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SGI-7079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sitravatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLC-0211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AXL for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AXL, FLT3 and ARK5 for Solid Tumor and Hematological Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AXL, FLT3 and NTRK for Solid Tumors and Blood Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0903 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Discontinued Products
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
May 22, 2017: BerGenBio Announces Start of Randomized Phase I/II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with Current Therapies in Melanoma
May 19, 2017: Abstract showing activity in MDS of BerGenBios first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017
Apr 04, 2017: Ignyta Announces New Data Highlighting Broad Potential of RXDX-106 at the 2017 AACR Annual Meeting
Mar 28, 2017: Ignyta Announces Multiple Presentations at the 2017 AACR Annual Meeting
Mar 06, 2017: Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma
Feb 17, 2017: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Jan 09, 2017: BerGenBio To Present At 9th Annual Biotech Showcase 2017
Jan 05, 2017: Mirati Therapeutics Provides Update On Glesatinib Clinical Trial And Pipeline Program
Jan 05, 2017: Mirati Therapeutics Provides Update On Sitravatinib Clinical Trial And Pipeline Program
Dec 08, 2016: New Breast Cancer Research Highlights BGB324 In Overcoming Immunotherapy Resistance
Dec 07, 2016: Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and Pipeline
Dec 05, 2016: BerGenBio Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML at ASH 2016
Nov 29, 2016: BerGenBio Reports Promising BGB324 Phase I/II Monotherapy Data in Patients with Lung Cancer at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Nov 29, 2016: Ignyta to Debut Preclinical Data on RXDX-106 at the 2016 EORTC-NCI-AACR Annual Meeting
Nov 17, 2016: Astellas Oncology Announces New Data in Acute Myeloid Leukemia to be Presented at the 2016 ASH Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indications, H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Astellas Pharma Inc, H1 2017
Pipeline by BerGenBio ASA, H1 2017
Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017
Pipeline by Celldex Therapeutics Inc, H1 2017
ipeline by Exelixis Inc, H1 2017
Pipeline by Ignyta Inc, H1 2017
Pipeline by Les Laboratoires ServierSAS, H1 2017
Pipeline by Mirati Therapeutics Inc, H1 2017
Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Pipeline by Oribase Pharma, H1 2017
Pipeline by Qurient Co Ltd, H1 2017
Pipeline by SignalChem Lifesciences Corp, H1 2017
Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Pipeline by Tolero Pharmaceuticals Inc, H1 2017
Dormant Products, H1 2017
Dormant Products, H1 2017 (Contd..1), H1 2017
Discontinued Products, H1 2017

List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *